Find Grants for School Districts
Find out if you qualify for verified grants for School Districts. Discover your eligibility and key funding details for School Districts from major foundations and government agencies.
Prevention and Intervention Approaches for Fetal Alcohol Spectrum Disorders (R34 Clinical Trial Optional)
Deadline: January 7, 2027
Opportunity Number: PAR-25-159
Agency: National Institutes of Health
Open Date: November 25, 2024
Close Date: January 7, 2027
Status: Posted
CFDA Numbers: 93.273
Prevention and Intervention Approaches for Fetal Alcohol Spectrum Disorders (R61/R33 Clinical Trial Optional)
Deadline: November 17, 2026
Opportunity Number: PAR-25-158
Agency: National Institutes of Health
Open Date: November 25, 2024
Close Date: November 17, 2026
Status: Posted
CFDA Numbers: 93.273
The Role of Work in Health Disparities in the U.S. (R01 Clinical Trials Optional)
Deadline: January 7, 2028
Opportunity Number: PAR-25-292
Agency: National Institutes of Health
Open Date: November 25, 2024
Close Date: January 7, 2028
Status: Posted
CFDA Numbers: 93.866, 93.361, 93.393, 93.307, 93.399, 93.396, 93.279, 93.242
Catalyze Product Definition Medical Device prototype design/testing and disease target identification and assay development (R61/R33 - Clinical Trial Not Allowed)
Deadline: December 23, 2027
Opportunity Number: RFA-HL-26-019
Agency: National Institutes of Health
Open Date: November 22, 2024
Close Date: December 23, 2027
Status: Posted
CFDA Numbers: 93.837, 93.233, 93.839, 93.838
Catalyze: Enabling Technologies and Transformative Platforms for HLBS Research (R33 - Clinical Trials Not Allowed)
Deadline: December 23, 2027
Opportunity Number: RFA-HL-26-016
Agency: National Institutes of Health
Open Date: November 22, 2024
Close Date: December 23, 2027
Status: Posted
CFDA Numbers: 93.839, 93.233, 93.838, 93.837
Catalyze: Product Definition Medical Device Prototype Optimization (R33 - Clinical Trial Not Allowed)
Deadline: December 23, 2027
Opportunity Number: RFA-HL-26-020
Agency: National Institutes of Health
Open Date: November 22, 2024
Close Date: December 23, 2027
Status: Posted
CFDA Numbers: 93.839, 93.233, 93.837, 93.838
Catalyze: Product Definition for Small Molecules, Biologics and Combination Products - Target Identification and Validation, and Preliminary Product/Lead Series Identification (R61/R33 Clinical Trials Not Allowed)
Deadline: December 23, 2027
Opportunity Number: RFA-HL-26-017
Agency: National Institutes of Health
Open Date: November 22, 2024
Close Date: December 23, 2027
Status: Posted
CFDA Numbers: 93.839, 93.838, 93.233, 93.837
Catalyze: Product Definition for Small Molecules, Biologics, and Combination Products - Preliminary Product/Lead Series Identification and Combination Product Prototype (R33 - Clinical Trial Not Allowed)
Deadline: December 23, 2027
Opportunity Number: RFA-HL-26-018
Agency: National Institutes of Health
Open Date: November 22, 2024
Close Date: December 23, 2027
Status: Posted
CFDA Numbers: 93.839, 93.233, 93.838, 93.837
Mood and Psychosis Symptoms during the Menopause Transition (R01 Clinical Trial Optional)
Deadline: January 7, 2028
Opportunity Number: PAR-25-281
Agency: National Institutes of Health
Open Date: November 22, 2024
Close Date: January 7, 2028
Status: Posted
CFDA Numbers: 93.242, 93.313
Mood and Psychosis Symptoms during the Menopause Transition (R21 Clinical Trial Optional)
Deadline: January 7, 2028
Opportunity Number: PAR-25-282
Agency: National Institutes of Health
Open Date: November 22, 2024
Close Date: January 7, 2028
Status: Posted
CFDA Numbers: 93.242, 93.313
Occupational Safety and Health Training Project Grants (T03)
Deadline: October 26, 2028
Opportunity Number: RFA-OH-25-003
Agency: Centers for Disease Control and Prevention - ERA
Open Date: November 22, 2024
Close Date: October 26, 2028
Status: Posted
CFDA Numbers: 93.262
Seamless Early-Stage Clinical Drug Development (Phase 1 to 2a) for Novel therapeutic Agents for the Spectrum of Alzheimer's Disease (AD) and AD-related Dementias (ADRD) (UG3/UH3 Clinical Trial Required)
Deadline: November 19, 2026
Opportunity Number: PAR-25-226
Agency: National Institutes of Health
Open Date: November 22, 2024
Close Date: November 19, 2026
Status: Posted
CFDA Numbers: 93.242
Utilizing Invasive Recording and Stimulating Opportunities in Humans to Advance Neural Circuitry Understanding of Mental Health Disorders (R01 Clinical Trial Optional)
Deadline: January 7, 2028
Opportunity Number: PAR-25-290
Agency: National Institutes of Health
Open Date: November 22, 2024
Close Date: January 7, 2028
Status: Posted
CFDA Numbers: 93.242
Utilizing Invasive Recording and Stimulating Opportunities in Humans to Advance Neural Circuitry Understanding of Mental Health Disorders (R21 Clinical Trial Optional)
Deadline: January 7, 2028
Opportunity Number: PAR-25-291
Agency: National Institutes of Health
Open Date: November 22, 2024
Close Date: January 7, 2028
Status: Posted
CFDA Numbers: 93.242
BRAIN Initiative: Promoting Health for All Through BRAIN Technology Partnerships (R34 - Clinical Trials Not Allowed)
Deadline: June 17, 2026
Opportunity Number: RFA-NS-25-016
Agency: National Institutes of Health
Open Date: November 21, 2024
Close Date: June 17, 2026
Status: Posted
CFDA Numbers: 93.173, 93.866, 93.273, 93.853, 93.286, 93.279, 93.867, 93.242, 93.213, 93.865
Feasibility Clinical Trials of Mind and Body Interventions for NCCIH High Priority Research Topics (R34 Clinical Trial Required)
Deadline: November 17, 2026
Opportunity Number: PAR-25-274
Agency: National Institutes of Health
Open Date: November 21, 2024
Close Date: November 17, 2026
Status: Posted
CFDA Numbers: 93.213
Innovative Research in Cancer Nanotechnology (IRCN; R01 Clinical Trial Not Allowed)
Deadline: May 4, 2026
Opportunity Number: PAR-25-106
Agency: National Institutes of Health
Open Date: November 21, 2024
Close Date: May 4, 2026
Status: Posted
CFDA Numbers: 93.394, 93.395
Investigator Initiated Clinical Trials of Complementary and Integrative Interventions Delivered Remotely or via mHealth (R01 Clinical Trial Required)
Deadline: November 17, 2026
Opportunity Number: PAR-25-268
Agency: National Institutes of Health
Open Date: November 21, 2024
Close Date: November 17, 2026
Status: Posted
CFDA Numbers: 93.213
Limited Competition: Competing Revisions to Support Clinical Trials in Somatic Cell Genome Editing (U19 Clinical Trial Required)
Deadline: February 13, 2026
Opportunity Number: RFA-RM-24-008
Agency: National Institutes of Health
Open Date: November 21, 2024
Close Date: February 13, 2026
Status: Posted
CFDA Numbers: 93.310
NCCIH Multi-Site Feasibility Clinical Trials of Mind and Body Interventions (R01 Clinical Trial Required)
Deadline: November 17, 2026
Opportunity Number: PAR-25-267
Agency: National Institutes of Health
Open Date: November 21, 2024
Close Date: November 17, 2026
Status: Posted
CFDA Numbers: 93.213
Neuromodulation/Neurostimulation Device Development for Mental Health Applications (R01 Clinical Trial Not Allowed)
Deadline: January 7, 2028
Opportunity Number: PAR-25-287
Agency: National Institutes of Health
Open Date: November 21, 2024
Close Date: January 7, 2028
Status: Posted
CFDA Numbers: 93.242
Neuromodulation/Neurostimulation Device Development for Mental Health Applications (R21 Clinical Trial Not Allowed)
Deadline: January 7, 2028
Opportunity Number: PAR-25-286
Agency: National Institutes of Health
Open Date: November 21, 2024
Close Date: January 7, 2028
Status: Posted
CFDA Numbers: 93.242
Personal Health Informatics for Delivering Actionable Insights to Individuals (R01 Clinical Trial Optional)
Deadline: January 7, 2027
Opportunity Number: PAR-25-235
Agency: National Institutes of Health
Open Date: November 21, 2024
Close Date: January 7, 2027
Status: Posted
CFDA Numbers: 93.242, 93.879
Screening, Brief Intervention and Referral to Treatment or Prevention (SBIRT/P) for alcohol, tobacco, and other drugs (ATOD) use and misuse in adult populations that experience health disparities (R01, Clinical Trial Required)
Deadline: May 7, 2027
Opportunity Number: PAR-26-001
Agency: National Institutes of Health
Open Date: November 21, 2024
Close Date: May 7, 2027
Status: Posted
CFDA Numbers: 93.307, 93.273, 93.399, 93.121, 93.279, 93.313
Understanding Expectancies in Cancer Symptom Management (R01 Clinical Trial Required)
Deadline: May 7, 2026
Opportunity Number: PAR-25-254
Agency: National Institutes of Health
Open Date: November 21, 2024
Close Date: May 7, 2026
Status: Posted
CFDA Numbers: 93.399
